Filter Results
:
(3)
Show Results For
-
All HBS Web
(3)
- Research (2)
- Faculty Publications (2)
Show Results For
-
All HBS Web
(3)
- Research (2)
- Faculty Publications (2)
Page 1 of
3
Results
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer...
View Details
Keywords:
MedImmune;
MedImmune Ventures;
AstraZeneca;
NeuProtect;
Corporate Venturing;
Biotechnology;
Venture Investing;
Venture Capital;
Health Care and Treatment;
Pharmaceutical Industry;
Financial Services Industry;
Biotechnology Industry;
United States;
Australia;
Europe;
London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- January 2014
- Teaching Plan
MedImmune Ventures
By: Richard Hamermesh and Andrew Otazo
"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets.
View Details
Keywords:
MedImmune Ventures;
NeuProtect;
Corporate Venture Capital;
Ron Laufer;
Australia;
Starfish Ventures;
AstraZeneca;
MEVE;
Healthcare;
Startup;
Venture Capital;
Business Startups;
Health Industry;
Australia;
United States
Hamermesh, Richard, and Andrew Otazo. "MedImmune Ventures." Harvard Business School Teaching Plan 814-039, January 2014.
- Web
Recruiting Partners - Health Care
McKesson Corporation MDLand Medical Consultants Network, Inc. MedImmune Medtronic, Inc. Memorial Sloan-Kettering Cancer Center Merck & Co., Inc. Millennium Medical Management LLC/Surgery Center of Viera Millipore Corporation Moderna...
View Details